Whitehawk Therapeutics, Inc. - 8-K Filing
Whitehawk Therapeutics expanded its ADC pipeline through an option agreement with Hangzhou DAC Biotechnology for access to CPT113 linker-payload technology, enabling up to five new programs. The company also highlighted data from DXC006 at ASCO and is enrolling patients in Phase 1 trials of HWK-007 and HWK-016. (Items: 8.01 Other Events On May 21, 2026, Whitehawk Therapeutics, Inc, 9.01 Financial Statements and Exhibits)
Tickers: $WHWK